Key facts
- This page summarizes William R. Newlin's Form 4 filing for ALPHA HEALTHCARE ACQUISITION CORP III (XAGE).
- 3 reported transactions and 3 derivative rows are listed below.
- Accepted by SEC: 18 Jul 2023, 20:37.
William R. Newlin - 14 Jul 2023 Form 4 Insider Report for ALPHA HEALTHCARE ACQUISITION CORP III (XAGE)
- Reporting relationship
- Director
- Issuer ticker
- XAGE
- Reported as of
- 14 Jul 2023
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 18 Jul 2023, 20:37:16 UTC
- Prior SEC filing
- 05 Aug 2022
- Source filing
- View source filing
- Reporting owner signature
- /s/ Randolph W. Hubbell, Attorney-in-Fact
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
William R. Newlin filed Form 4 for ALPHA HEALTHCARE ACQUISITION CORP III (XAGE) on 18 Jul 2023.
Change
- Previous filing in this sequence was filed on 05 Aug 2022.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
CTCX
holding
Common Stock
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 1,249,062
- Date
- 14 Jul 2023
- Ownership
- Newlin Investment 1 LLC
- Footnotes
- F1
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
CTCX
transaction
Derivative
Stock Option (right to buy)
Award
- Transaction value
- Shares
- +108,167
- Change %
- Price
- Shares after
- 108,167
- Date
- 14 Jul 2023
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 108,167
- Exercise price
- $2.11
- Footnotes
- F2, F3
CTCX
transaction
Derivative
Common Stock Warrants
Other
- Transaction value
- Shares
- +482
- Change %
- Price
- Shares after
- 482
- Date
- 14 Jul 2023
- Ownership
- Newlin Investment 1 LLC
- Underlying class
- Common Stock
- Underlying amount
- 482
- Exercise price
- $6.71
- Footnotes
- F1, F4, F5
CTCX
transaction
Derivative
Common Stock Warrants
Other
- Transaction value
- Shares
- +35,304
- Change %
- Price
- Shares after
- 35,304
- Date
- 14 Jul 2023
- Ownership
- Newlin Investment 1 LLC
- Underlying class
- Common Stock
- Underlying amount
- 35,304
- Exercise price
- $2.39
- Footnotes
- F1, F4, F5
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 5 footnotes
Footnote F1
Mr. Newlin is Chairman and Founder of Newlin Investment 1 LLC. By virtue of this relationship, Mr. Newlin may be deemed to share beneficial ownership of the securities held of record by Newlin Investment 1 LLC. Mr. Newlin disclaims any such beneficial ownership except to the extent of his pecuniary interest.
Footnote F2
Options to purchase 108,167 shares of common stock of Legacy Carmell (as defined below) granted on September 23, 2021, which vest as follows: 25% vested on September 23, 2021 and the remaining 75% becomes vested in 36 equal monthly installments thereafter, subject to continued service through each vesting date.
Footnote F3
On July 14, 2023, Alpha Healthcare Acquisition Corp. III ("ALPA") consummated a business combination (the "Business Combination") by and among ALPA, Candy Merger Sub, Inc., a Delaware corporation ("Merger Sub") and Carmell Regen Med Corporation, a Delaware corporation ("Legacy Carmell"), ALPA changed its name to "Carmell Therapeutics Corporation" and Merger Sub merged with and into Legacy Carmell. As part of the Business Combination, each Legacy Carmell stock option was exchanged for a stock option to acquire 0.06154 shares of common stock of Carmell Therapeutics Corporation.
Footnote F4
These warrants are currently exercisable.
Footnote F5
As part of the Business Combination, (i) existing warrants to purchase common stock of Legacy Carmell were exchanged for 0.06154 warrants to purchase shares of common stock of Carmell Therapeutics Corporation and (ii) existing Series C-1 warrants to purchase common stock of Legacy Carmell were exchanged for 0.06684 warrants to purchase shares of common stock of Carmell Therapeutics Corporation.